NASDAQ:CLGN CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis $2.33 -0.09 (-3.72%) Closing price 08/1/2025 03:57 PM EasternExtended Trading$2.31 -0.02 (-1.07%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CollPlant Biotechnologies Stock (NASDAQ:CLGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CLGN alerts:Sign Up Key Stats Today's Range$2.22▼$2.5050-Day Range$1.35▼$4.5452-Week Range$1.31▼$5.45Volume20,491 shsAverage Volume64,108 shsMarket Capitalization$29.64 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingBuy Company Overview CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel. Read More CollPlant Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreCLGN MarketRank™: CollPlant Biotechnologies scored higher than 43% of companies evaluated by MarketBeat, and ranked 633rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingCollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.Read more about CollPlant Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.44) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CollPlant Biotechnologies is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CollPlant Biotechnologies is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCollPlant Biotechnologies has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CollPlant Biotechnologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.28% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently increased by 45.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollPlant Biotechnologies does not currently pay a dividend.Dividend GrowthCollPlant Biotechnologies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.28% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently increased by 45.61%, indicating that investor sentiment is decreasing significantly. News and Social MediaN/ANews SentimentN/A Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of CollPlant Biotechnologies is held by insiders.Percentage Held by InstitutionsOnly 21.69% of the stock of CollPlant Biotechnologies is held by institutions.Read more about CollPlant Biotechnologies' insider trading history. Receive CLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address CLGN Stock News HeadlinesCollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial OperationsJuly 14, 2025 | prnewswire.comCollPlant Biotechnologies Ltd. (CLGN) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. | The Oxford Club (Ad)CollPlant shares rise on expanded partnership with STEMCELL TechnologiesJune 9, 2025 | msn.comCOLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIESJune 9, 2025 | prnewswire.comCOLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTSJune 4, 2025 | prnewswire.comCollPlant Biotechnologies shares slide after announces capital raise of $3.6M through registered direct offeringMay 30, 2025 | msn.comCOLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULESMay 30, 2025 | prnewswire.comSee More Headlines CLGN Stock Analysis - Frequently Asked Questions How have CLGN shares performed this year? CollPlant Biotechnologies' stock was trading at $3.60 at the start of the year. Since then, CLGN stock has decreased by 35.3% and is now trading at $2.33. How were CollPlant Biotechnologies' earnings last quarter? CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) announced its earnings results on Wednesday, June, 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.24. The firm earned $2.06 million during the quarter, compared to analysts' expectations of $9.76 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 87.33% and a negative net margin of 560.92%. When did CollPlant Biotechnologies IPO? CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager. Who are CollPlant Biotechnologies' major shareholders? CollPlant Biotechnologies' top institutional shareholders include Villere ST Denis J & Co. LLC (4.30%). How do I buy shares of CollPlant Biotechnologies? Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CollPlant Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA). Company Calendar Last Earnings6/04/2025Today8/02/2025Next Earnings (Estimated)8/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:CLGN CIK1631487 Webwww.collplant.com Phone972732325600Fax972-73-232-5602Employees70Year FoundedN/APrice Target and Rating Average Price Target for CollPlant Biotechnologies$11.50 High Price Target$12.00 Low Price Target$11.00 Potential Upside/Downside+393.6%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.61 million Net Margins-560.92% Pretax Margin-560.92% Return on Equity-87.33% Return on Assets-65.31% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio4.23 Sales & Book Value Annual Sales$510 thousand Price / Sales58.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book1.97Miscellaneous Outstanding Shares12,720,000Free Float11,495,000Market Cap$29.64 million OptionableOptionable Beta1.45 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CLGN) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share CollPlant Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.